


Please delete the Abstract, and replace with the following Abstract:

Abstract

The present invention is directed to a compound of formula I:



or a pharmaceutically acceptable salt thereof, wherein:

R₁ is selected from the group consisting of H and methyl; and

R₂ is selected from the group consisting of H and methyl.

The compounds possess useful nitric oxide synthetase inhibiting activity, and are expected to be useful in the treatment or prophylaxis of a disease or condition in which the synthesis or over synthesis of nitric oxide forms a contributory part.

IN THE CLAIMS

Please amend Claim 28 as follows:

28. (amended) A compound selected from the group consisting of: (2S, 4E)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2S, 4Z)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2R/S, 4E)-2-Amino-4,5-dimethyl-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2R/S, 4Z)-2-Amino-4,5-dimethyl-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2S, 4E)-2-Amino-4-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2S, 4Z)-2-Amino-4-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2S, 4E)-2-Amino-5-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2S, 4Z)-2-Amino-5-methyl-6-(1-iminoethylamino)-hept-4-enoic acid;
 (2R, 4E)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid; and
 (2R, 4Z)-2-Amino-6-(1-iminoethylamino)-hept-4-enoic acid.